The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
Open accessAbstract
Alzheimer's disease (AD) is the most common form of dementia among the elderly. In AD patients, memory loss is accompanied by the formation of beta-amyloid plaques and the appearance of tau in a pathological form. Given the lack of effective treatments for AD, the development of new management strategies for these patients is critical. The continued failure to find effective therapies using molecules aimed at addressing the anti-beta amyloid pathology has led researchers to focus on other non-amyloid-based approaches to restore memory function. Promising non-amyloid related candidate targets include phosphosdiesterases (PDEs), and indeed, Rolipram, a specific PDE4 inhibitor, was the first compound found to effectively restore cognitive deficits in animal models of AD. More recently, PDE5 inhibitors have also been shown to effectively restore memory function. Accordingly, inhibitors of other members of the PDE family may also improve memory performance in AD and non-AD animal models. Hence, in this review, we will summarize the data supporting the use of PDE inhibitors as cognitive enhancers and we will discuss the possible mechanisms of action underlying these effects. We shall also adopt a medicinal chemistry perspective that leads us to propose the most promising PDE candidates on the basis of inhibitor selectivity, brain distribution, and mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Abel, T., Nguyen, P. V., Barad, M., Deuel, T. A. S., Kandel, E. R., & Bourtchouladze, R. (1997) · Cell · doi:10.1016/s0092-8674(00)81904-2 · Cited by 1,217
Harrison, P. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1761-y · Cited by 693
Impey, S., Mark, M., Villacres, E. C., Poser, S., Chavkin, C., & Storm, D. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80120-8 · Cited by 593
Sakamoto, K., Karelina, K., & Obrietan, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07080.x · Cited by 543
Bernabeu, R., Bevilaqua, L., Ardenghi, P., Bromberg, E., Schmitz, P., Bianchin, M., Izquierdo, I., & Medina, J. H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.7041 · Cited by 498
Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling
Conti, M., Richter, W., Mehats, C., Livera, G., Park, J.-Y., & Jin, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r200029200 · Cited by 481
Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues
Lakics, V., Karran, E. H., & Boess, F. G. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.05.004 · Cited by 463
Cited by
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
Salehi, B., Berkay Yılmaz, Y., Antika, G., Boyunegmez Tumer, T., Fawzi Mahomoodally, M., Lobine, D., Akram, M., Riaz, M., Capanoglu, E., Sharopov, F., et al. (2019) · Biomolecules · doi:10.3390/biom9080356 · Cited by 416
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Metadata
- Authors
- García-Osta, A., Cuadrado-Tejedor, M., García-Barroso, C., Oyarzábal, J., & Franco, R.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-10-10
- Volume
- 3
- Issue
- 11
- Pages
- 832-844
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2196088104
- Cited by
- 259
- References
- 143
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. https://app.cochat.ai/papers/10.1021/cn3000907
- The paper
- García-Osta, A., Cuadrado-Tejedor, M., García-Barroso, C., Oyarzábal, J., & Franco, R. (2012). Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/cn3000907
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.